Developer docs
API playgroundTry for free, no card

Search company profiles

NeuMoDx Molecular

Full company profile

uuid00036pv

Namestring
NeuMoDx Molecular
Websiteurl
neumodx.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

NeuMoDx Molecular, Inc. is a molecular diagnostics company founded in 2012 and headquartered in Ann Arbor, Michigan, that developed automated sample-to-result systems for clinical molecular diagnostic (MDx) testing. The company's core product platform integrated nucleic acid extraction, amplification, and detection into a closed, cartridge-based instrument workflow intended for hospital and reference laboratory settings, reducing hands-on time relative to legacy multi-step MDx protocols.

The company was privately held and funded through a series of equity rounds totaling approximately $66M, with participation from healthcare-focused venture investors including Arboretum Ventures, Baird Capital, Pfizer Venture Investments, Clarevia Ventures, and Wolverine Venture Fund. Jeff Williams served as Chairman and CEO. The company operated with a focused organization of 11–50 employees, consistent with an instrument-and-consumables commercialization stage prior to exit.

In 2021, NeuMoDx was acquired by Qiagen, a global molecular diagnostics and sample technologies provider, and now operates as a wholly owned subsidiary within Qiagen's diagnostics portfolio. The standalone business model relied on instrument placement paired with recurring cartridge/consumable revenue, the standard razor-and-blade economics of the clinical MDx industry, though specific pricing, contract structures, and customer counts are not disclosed in the available source data. The current public web presence at neumodx.com is a loader/verification page with no substantive product, pricing, or operational detail.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAnn Arbor, United States
HQ citystring
Ann Arbor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
molecular diagnostics, MDx testing, clinical diagnostics, automated PCR systems, diagnostic instruments
Industry2 codes
1Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
CodeHLAHAAADPrimaryYes
2Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
CodeHLAHAOAIPrimaryNo
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeuMoDx Molecular develops molecular diagnostic (MDx) testing solutions for clinical laboratories. The company focuses on building automated systems and assays that enable molecular testing workflows used by healthcare and laboratory customers.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Molecular diagnostic (MDx) testing solutions
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Roche Diagnostics (cobas)
TypeBroad incumbent
Description

Roche's cobas molecular diagnostics platform competes with NeuMoDx in centralized and high-volume hospital lab settings, and Roche also owns GenMark Diagnostics for a similar automated molecular footprint.

2Becton Dickinson (BD)
TypeBroad incumbent
Description

BD's molecular diagnostics business, including the BD MAX system, directly competes with NeuMoDx in automated sample-to-answer PCR testing for clinical laboratories and hospitals.

3GenMark Diagnostics
TypeDirect peer
Description

GenMark (acquired by Roche) developed the ePlex automated molecular diagnostics platform, a close peer to NeuMoDx in offering sample-to-answer PCR-based testing for hospital labs.

4bioMérieux (BioFire)
TypeDirect peer
Description

bioMérieux's BioFire FilmArray system is a leading fully-automated molecular diagnostics platform for syndromic testing, directly comparable to NeuMoDx's automated PCR value proposition in clinical settings.

5Hologic (Panther)
TypeDirect peer
Description

Hologic's Panther system is a fully-automated molecular diagnostics platform with a similar value proposition to NeuMoDx for women's health, infectious disease, and hospital lab testing customers.

6Abbott (m2000 / Alinity m)
TypeBroad incumbent
Description

Abbott's m2000 and Alinity m molecular diagnostics platforms compete with NeuMoDx in central lab and hospital molecular testing, particularly in infectious disease and viral load monitoring.

7Luminex (DiaSorin)
TypeDirect peer
Description

Luminex (acquired by DiaSorin) developed the ARIES and VERIGENE automated molecular diagnostics systems, providing a directly comparable platform to NeuMoDx in the hospital molecular lab segment.

8T2 Biosystems
TypeEmerging player
Description

T2 Biosystems is an emerging molecular diagnostics company developing rapid, automated molecular detection platforms for clinical applications, partially overlapping with NeuMoDx's automated testing focus.

9Cepheid
TypeDirect peer
Description

Cepheid (a Danaher subsidiary) is the leading fully-automated molecular diagnostics PCR platform competitor with its GeneXpert system, directly comparable to NeuMoDx's automated PCR platform in serving hospital and clinical lab customers.

10Qiagen (parent company)
TypeBroad incumbent
Description

Qiagen is the strategic acquirer of NeuMoDx and operates its own molecular diagnostics portfolio (QIAstat-Dx, etc.), making it both the parent and a meaningful internal benchmark for NeuMoDx's automated PCR roadmap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuMoDx Molecular

Molecular Diagnosticsneumodx.com

What NeuMoDx Molecular does

NeuMoDx Molecular, Inc. is a molecular diagnostics company founded in 2012 and headquartered in Ann Arbor, Michigan, that developed automated sample-to-result systems for clinical molecular diagnostic (MDx) testing. The company's core product platform integrated nucleic acid extraction, amplification, and detection into a closed, cartridge-based instrument workflow intended for hospital and reference laboratory settings, reducing hands-on time relative to legacy multi-step MDx protocols.

The company was privately held and funded through a series of equity rounds totaling approximately $66M, with participation from healthcare-focused venture investors including Arboretum Ventures, Baird Capital, Pfizer Venture Investments, Clarevia Ventures, and Wolverine Venture Fund. Jeff Williams served as Chairman and CEO. The company operated with a focused organization of 11–50 employees, consistent with an instrument-and-consumables commercialization stage prior to exit.

In 2021, NeuMoDx was acquired by Qiagen, a global molecular diagnostics and sample technologies provider, and now operates as a wholly owned subsidiary within Qiagen's diagnostics portfolio. The standalone business model relied on instrument placement paired with recurring cartridge/consumable revenue, the standard razor-and-blade economics of the clinical MDx industry, though specific pricing, contract structures, and customer counts are not disclosed in the available source data. The current public web presence at neumodx.com is a loader/verification page with no substantive product, pricing, or operational detail.

NeuMoDx Molecular firmographics

Firmographics
Name
NeuMoDx Molecular
Website
https://neumodx.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

NeuMoDx Molecular industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
akta.pro secondary industry
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

  • Molecular diagnostics
  • MDx testing
  • Clinical diagnostics
  • Automated PCR systems
  • Diagnostic instruments

Where NeuMoDx Molecular is headquartered

Location

Headquarters

HQ city
Ann Arbor
HQ country
United States
HQ region
North America

Markets served

NeuMoDx Molecular business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

NeuMoDx Molecular product offering

Product offering

Core offering

NeuMoDx Molecular develops molecular diagnostic (MDx) testing solutions for clinical laboratories. The company focuses on building automated systems and assays that enable molecular testing workflows used by healthcare and laboratory customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular diagnostic (MDx) testing solutions

Companies that use NeuMoDx Molecular

Customer profile

Ideal customer profiles1 record

NeuMoDx Molecular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

NeuMoDx Molecular partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

NeuMoDx Molecular competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics (cobas): Roche's cobas molecular diagnostics platform competes with NeuMoDx in centralized and high-volume hospital lab settings, and Roche also owns GenMark Diagnostics for a similar automated molecular footprint.
  • Becton Dickinson (BD): BD's molecular diagnostics business, including the BD MAX system, directly competes with NeuMoDx in automated sample-to-answer PCR testing for clinical laboratories and hospitals.
  • Abbott (m2000 / Alinity m): Abbott's m2000 and Alinity m molecular diagnostics platforms compete with NeuMoDx in central lab and hospital molecular testing, particularly in infectious disease and viral load monitoring.
  • Qiagen (parent company): Qiagen is the strategic acquirer of NeuMoDx and operates its own molecular diagnostics portfolio (QIAstat-Dx, etc.), making it both the parent and a meaningful internal benchmark for NeuMoDx's automated PCR roadmap.

Direct peers

  • GenMark Diagnostics: GenMark (acquired by Roche) developed the ePlex automated molecular diagnostics platform, a close peer to NeuMoDx in offering sample-to-answer PCR-based testing for hospital labs.
  • bioMérieux (BioFire): bioMérieux's BioFire FilmArray system is a leading fully-automated molecular diagnostics platform for syndromic testing, directly comparable to NeuMoDx's automated PCR value proposition in clinical settings.
  • Hologic (Panther): Hologic's Panther system is a fully-automated molecular diagnostics platform with a similar value proposition to NeuMoDx for women's health, infectious disease, and hospital lab testing customers.
  • Luminex (DiaSorin): Luminex (acquired by DiaSorin) developed the ARIES and VERIGENE automated molecular diagnostics systems, providing a directly comparable platform to NeuMoDx in the hospital molecular lab segment.
  • Cepheid: Cepheid (a Danaher subsidiary) is the leading fully-automated molecular diagnostics PCR platform competitor with its GeneXpert system, directly comparable to NeuMoDx's automated PCR platform in serving hospital and clinical lab customers.

Emerging players

  • T2 Biosystems: T2 Biosystems is an emerging molecular diagnostics company developing rapid, automated molecular detection platforms for clinical applications, partially overlapping with NeuMoDx's automated testing focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

NeuMoDx Molecular social profiles

Digital presence

NeuMoDx Molecular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuMoDx Molecular leadership team

Management profile

Number of profiles

Profiles1 record

NeuMoDx Molecular funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuMoDx Molecular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuMoDx Molecular

What does NeuMoDx Molecular do?

NeuMoDx Molecular develops molecular diagnostic (MDx) testing solutions for clinical laboratories. The company focuses on building automated systems and assays that enable molecular testing workflows used by healthcare and laboratory customers.

Is NeuMoDx Molecular a public or private company?

NeuMoDx Molecular is a private company. It is classified as corporate owned and is currently acquired.

When was NeuMoDx Molecular founded?

NeuMoDx Molecular was founded in 2012. It employs 11 to 50 people.

Where is NeuMoDx Molecular based?

NeuMoDx Molecular is headquartered in Ann Arbor, United States, in the North America region.

Who are NeuMoDx Molecular's main competitors?

Broad incumbents on record are Roche Diagnostics (cobas), Becton Dickinson (BD), Abbott (m2000 / Alinity m) and Qiagen (parent company). Direct peers are GenMark Diagnostics, bioMérieux (BioFire), Hologic (Panther), Luminex (DiaSorin) and Cepheid. T2 Biosystems is listed as an emerging player.

Does NeuMoDx Molecular have an API?

No public API is recorded for NeuMoDx Molecular.

What industry is NeuMoDx Molecular in?

NeuMoDx Molecular's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Respiratory Infection Diagnostic Market Analysis Report 2023: Explore the Rapidly Changing Market as Competitors Jockey for Position in New MarketsResearchAndMarkets.com released a global respiratory infection diagnostic market analysis report examining the shift from centralized COVID-19 testing to decentralized point-of-care testing across health facilities, clinics, physician offices, and potential home settings. The report identifies multiplex testing technologies as a key growth driver that reduces costs and time-to-result while enabling simultaneous detection of multiple respiratory pathogens including COVID-19, influenza, and RSV. Key recent industry developments highlighted include Cue Health's IPO filing, Qiagen's acquisition of NeuMoDx Molecular, multiple CE mark approvals for respiratory panels, and ongoing FDA emergency use authorizations for combination tests.PR NewswireSaliva-based Screening, a "Game Changer" in Infection Diagnostics to Expand at 8% through 2031Persistence Market Research released industry analysis showing the global saliva-based screening market was valued at US$ 277 million in 2020 and is projected to grow at a compound annual growth rate of 8% through 2031. Key drivers include advances in point-of-care testing technology, the non-invasive nature of saliva collection, and expanding applications such as HIV screening. Notable market activity includes Salimetrics launching a new salivary immunoglobulin G ELISA kit in January 2020 and QIAGEN N.V. acquiring 80.1% of NeuMoDx Molecular, Inc. for US$ 248 million in September 2020.